Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Scott H. Davis who wrote (2568)	1/15/2001 10:14:51 PM
From: Jibacoa	Read Replies (2) of 52153

No, I don't know who the sponsor was. What was encouraging to me is to see that some "cancer vaccines" are showing some preliminary "hopeful" results. Of course we will know more when and if they decide to go into a Phase III, which is still most likely some years away. In that field I am following Biomira (BIOM) which has shown some encouraging results on the Phase II of their Theratope breast cancer vaccine and now have completed enrollment (over 900 patients) on their Phase III using a new version of the vaccine which reportedly is 100 times more potent than the one they used on Phase II. If their Theratope vaccine gets FDA approval for breast cancer, it is possible that they could then prove the vaccine could be used for ovarian and colon cancer, since they also carry the Muc-1 antigen. They also are in the process of evaluating another vaccine (BLP25) for lung cancer, on which they have an even higher hope of success than on Theratope. On their preliminary (Phase II) trial, Biomira's Theratope has shown better results than Herceptin. Reportedly Theratope has shown benefit on 80% of cases and Herceptin is helpful in only 30%. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next